Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (AMRN) delivers innovative cardiovascular therapeutics through advanced lipid science, anchored by its FDA-approved therapy VASCEPA®. This page provides direct access to official company announcements, clinical research updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases covering drug approvals, global expansion efforts, and peer-reviewed study results. Key updates include milestones from the landmark REDUCE-IT trial, intellectual property developments, and strategic partnerships enhancing patient access to cardiovascular care solutions.
All content is sourced from Amarin's corporate communications, ensuring accuracy and timeliness. Bookmark this page for streamlined tracking of AMRN's progress in addressing persistent cardiovascular risk through scientifically validated therapies.
Amarin Corporation has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company maintained an average closing share price of at least $1.00 over 10 consecutive business days ending April 28, 2025, meeting Rule 5550(a)(2) requirements.
The announcement came on April 29, 2025, with confirmation from Nasdaq's Listing Qualifications Department that the matter is now closed. This development follows Amarin's ADS ratio change, which was implemented to secure the company's public listing.
CEO Aaron Berg emphasized this as an important milestone, stating that with the listing compliance secured, Amarin will continue focusing on maximizing the global value of their product VASCEPA/VAZKEPA for patient benefit. The company is now in full compliance with all Nasdaq listing requirements and will maintain its trading status on the exchange.
Amarin Corporation (NASDAQ: AMRN) has scheduled its first quarter 2025 financial results announcement and conference call for May 7, 2025. The company will release its Q1 2025 results before market opening, followed by a conference call at 8:00 a.m. ET.
The call will feature Aaron Berg, President & CEO, along with senior management team members, who will discuss the quarterly results and conduct a Q&A session.
- U.S. Dial-in: 888-506-0062
- International Dial-in: 973-528-0011
- Access Code: 253130
For those unable to attend live, a replay will be available through:
- U.S. Replay: 877-481-4010
- International Replay: 919-882-2331
- Replay Access Code: 52230
Investors can also access the live call through the investor relations section at www.amarincorp.com, where a replay will be posted after the event.
Amarin (NASDAQ: AMRN) has announced a 1-for-20 ADS ratio change effective April 11, 2025. This strategic move will adjust the ratio from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.
The primary objective is to increase the per-share market price of Amarin's ADSs to meet Nasdaq's minimum bid price requirement of $1.00 and maintain the company's listing on The Nasdaq Capital Market. The company notes that there is no guarantee that the post-change trading price will be exactly twenty times the pre-change price.
The ratio change will not affect Amarin's ordinary shares, and the ADSs will continue trading under the symbol 'AMRN' on The Nasdaq Capital Market.
Amarin (NASDAQ: AMRN) has announced the immediate appointment of Michael Torok to its Board of Directors. Torok, who is the Co-Founder and Managing Director of investment firm JEC Capital Partners, brings financial expertise and board experience to the position.
Board Chairman Odysseas Kostas, MD, welcomed Torok, highlighting his financial background and alignment with shareholder interests. Torok expressed enthusiasm about working with fellow directors and senior management to maximize shareholder value, emphasizing the board's commitment to transparency.
Amarin (NASDAQ:AMRN) presented key data at ACC.25 demonstrating the mechanistic effects of eicosapentaenoic acid (EPA) and VASCEPA®/VAZKEPA®. The research showed that EPA effectively inhibited oxidation in lipoproteins, particularly in Lp(a)-enriched plasma, which is associated with increased cardiovascular risk.
The studies also revealed positive results when combining EPA with GLP-1 receptor agonist liraglutide, showing enhanced expression of detoxification proteins in endothelial cells during inflammation. Additionally, a recent REDUCE-IT analysis published in JAHA demonstrated that VASCEPA/VAZKEPA provided cardiovascular risk reduction benefits in patients with well-controlled LDL-C levels (<55 mg/dL), highlighting its value as a complementary therapy to standard statin treatment.
A Concerned Shareholder Group, owning approximately 15 million shares of Amarin (NASDAQ: AMRN), has issued an open letter urging the company's Board to initiate an immediate strategic review. The shareholders express disappointment with the company's performance, noting that AMRN's share price has dropped nearly 80% to $0.43 since the Board's reconstitution in February 2023, when it traded at $2.03.
Despite announcing a $50 million share repurchase plan in early 2024 when shares were at $1.15, the company has not executed the buyback. Instead, Amarin recently announced a 1-for-20 reverse stock split. The shareholders highlight that Amarin's market capitalization is approximately $185 million, despite having zero debt and nearly $300 million in cash (~$0.75/share).
Amarin (NASDAQ:AMRN) has announced new in vitro mechanistic research data on eicosapentaenoic acid (EPA) to be presented at the American College of Cardiology's Annual Scientific Session & Expo (March 29-31, 2025, Chicago).
The research focuses on two key areas: the antioxidant effects of EPA on lipoprotein(a) [Lp(a)]-enriched plasma and the combined effects of EPA with GLP-1 receptor agonists on antioxidant protein expression in endothelial cells during inflammation.
Two moderated poster presentations will be available on March 29th, 2025: one at 11:30am ET examining EPA's role in limiting Lp(a)-enriched plasma oxidation, and another at 11:42am ET investigating how EPA enhances detoxification protein expression when combined with GLP-1 agonists in endothelial cells.
Amarin (NASDAQ: AMRN) has announced plans to implement a 1-for-20 ratio change in its American Depositary Shares (ADS) program, expected to take effect around April 11, 2025. The adjustment will modify the current 1:1 ratio between ADS and ordinary shares to 1:20.
This strategic move aims to boost the per-share market price of Amarin's ADSs to meet Nasdaq's minimum bid requirement of $1.00 and maintain its listing on The Nasdaq Capital Market. The company's ordinary shares will remain unaffected, and the ADSs will continue trading under the symbol 'AMRN'.
Holders of uncertificated ADSs will experience automatic conversion, while those with certificated ADSs must surrender them for cancellation to receive new ones. Fractional ADSs will be sold, with net proceeds distributed to affected holders.
Amarin (NASDAQ: AMRN) reported Q4 2024 financial results with total revenues of $62.3 million, down 17% from $74.7 million in Q4 2023. The company ended 2024 with a cash position of $294.2 million and no debt.
Q4 net product revenue was $60.1 million, with U.S. revenue at $44.2 million, European revenue at $4.0 million, and Rest of World revenue at $11.9 million. The company reported a Q4 net loss of $48.6 million, or $0.12 per share.
Amarin announced a 1-for-20 ADS ratio change, expected to be effective April 11, 2025, to maintain Nasdaq listing compliance. The company expanded VASCEPA/VAZKEPA access to six additional global markets including Italy, China, and Australia, with progress in 16 more countries.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
